tbuckley/cabot-search huggingface dataset:
Mutations in γ-secretase subunit–encoding PSENEN underlie Dowling-Degos disease associated with acne inversa
Authors: Damian J. Ralser, F. Buket Ü. Basmanav, Aylar Tafazzoli, Jade Wititsuwannakul, Sarah Delker, Sumita Danda, Holger Thiele, Sabrina Wolf, Michélle Busch, Susanne A. Pulimood, Janine Altmüller, Peter Nürnberg, Didier Lacombe, Uwe Hillen, Jörg Wenzel, Jorge Frank, Benjamin Odermatt, Regina C. Betz
Journal: Journal of Clinical Investigation (2017)

Dowling-Degos disease (DDD) is an autosomal-dominant disorder of skin pigmentation associated with mutations in keratin 5 (KRT5), protein O-fucosyltransferase 1 (POFUT1), or protein O-glucosyltransferase 1 (POGLUT1). Here, we have identified 6 heterozygous truncating mutations in PSENEN, encoding presenilin enhancer protein 2, in 6 unrelated patients and families with DDD in whom mutations in KRT5, POFUT1, and POGLUT1 have been excluded. Further examination revealed that the histopathologic feature of follicular hyperkeratosis distinguished these 6 patients from previously studied individuals with DDD. Knockdown of psenen in zebrafish larvae resulted in a phenotype with scattered pigmentation that mimicked human DDD. In the developing zebrafish larvae, in vivo monitoring of pigment cells suggested that disturbances in melanocyte migration and differentiation underlie the DDD pathogenesis associated with PSENEN. Six of the PSENEN mutation carriers presented with comorbid acne inversa (AI), an inflammatory hair follicle disorder, and had a history of nicotine abuse and/or obesity, which are known trigger factors for AI. Previously, PSENEN mutations were identified in familial AI, and comanifestation of DDD and AI has been reported for decades. The present work suggests that PSENEN mutations can indeed cause a comanifestation of DDD and AI that is likely triggered by predisposing factors for AI. Thus, the present report describes a DDD subphenotype in PSENEN mutation carriers that is associated with increased susceptibility to AI.
Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)
Authors: Catherine S. Diefenbach, Fangxin Hong, Kevin A David, Jonathon Cohen, Michael Robertson, Ranjana Advani, Neil D. Palmisiano, Richard F. Ambinder, Brad S Kahl, Stephen Ansell
Journal: Blood (2016)
T cells control the generation of nanomolar-affinity anti-glycan antibodies
Authors: Zinaida Polonskaya, Shenglou Deng, Anita Sarkar, Lisa Kain, Marta Comellas-Aragones, Craig S. McKay, Katarzyna Kaczanowska, Marie Holt, Ryan McBride, Valle Palomo, Kevin M. Self, Seth Taylor, Adriana Irimia, Sanjay R. Mehta, Jennifer M. Dan, Matthew Brigger, Shane Crotty, Stephen P. Schoenberger, James C. Paulson, Ian A. Wilson, Paul B. Savage, M.G. Finn, Luc Teyton
Journal: Journal of Clinical Investigation (2017)

Vaccines targeting glycan structures at the surface of pathogenic microbes must overcome the inherent T cell-independent nature of immune responses against glycans. Carbohydrate conjugate vaccines achieve this by coupling bacterial polysaccharides to a carrier protein that recruits heterologous CD4 T cells to help B cell maturation. Yet they most often produce low- to medium-affinity immune responses of limited duration in immunologically fit individuals and disappointing results in the elderly and immunocompromised patients. Here, we hypothesized that these limitations result from suboptimal T cell help. To produce the next generation of more efficacious conjugate vaccines, we have explored a synthetic design aimed at focusing both B cell and T cell recognition to a single short glycan displayed at the surface of a virus-like particle. We tested and established the proof of concept of this approach for 2 serotypes of Streptococcus pneumoniae. In both cases, these vaccines elicited serotype-specific, protective, and long-lasting IgG antibodies of nanomolar affinity against the target glycans in mice. We further identified a requirement for CD4 T cells in the anti-glycan antibody response. Our findings establish the design principles for improved glycan conjugate vaccines. We surmise that the same approach can be used for any microbial glycan of interest.
Autologous Hematopotoietic Stem Cell Transplantation in Multiple Sclerosis with An Intermediate Intensity Conditioning Regimen: The Italian Multi-Centre Experience
Authors: Riccardo Saccardi, MariaPia Sormani, Massimo Di Gioia, Alberto Bosi, Antonio Cuneo, Ignazio Majolino, Luigi Cavanna, Fabio Ciceri, Federico Papineschi, Marcellina Mangoni, Giorgio La Nasa, Massimo Pini, Angelo Guerrasio, Francesco Onida, Francesca Gualandi, Giuseppe Irrera, Paolo Di Bartolomeo, Amedea Donelli, Luigi Gugliotta, Luisa Vuolo, Gianluigi Mancardi
Journal: Blood (2011)
Abstract P4-12-03: Estrogen receptor-positive breast cancer in <i>BRCA1</i> mutation carriers shows a BRCAness profile, suggesting sensitivity to drugs targeting homologous recombination deficiency
Authors: EH Lips, R Debipersad, E Scheerman, L Mulder, GS Sonke, LE van der Kolk, J Wessling, FBL Hogervorst, PM Nederlof
Journal: Cancer Research (2017)

Abstract Background As estrogen receptor (ER)-positive breast cancer in BRCA1 mutation carriers arises at an older age with less aggressive tumor characteristics than ER negative BRCA1 mutated breast cancer, it has been suggested that these tumors are 'sporadic' and not BRCA1-driven. With the introduction of targeted treatments specific for tumors with a non-functioning BRCA1 or BRCA2 gene, the question whether the BRCA genes are impaired in the tumor, is highly relevant. Therefore, we performed genomic profiling of BRCA1-mutated ER+ tumors. Methods Genomic profiling, BRCA1 promoter methylation assessment, and loss of heterozygosity (LOH) analysis were done on 16 BRCA1-mutated ER+ tumors. Results were compared with 57 BRCA1-mutated ER- tumors, 36 BRCA2-mutated ER+ associated tumors, and 182 sporadic ER+ tumors. Results The genomic profile of BRCA1-mutated ER+ tumors was different from BRCA1-mutated ER- breast tumors, but highly similar to BRCA2-mutated ER+ tumors. In 83% of the BRCA1-mutated ER+ tumors, loss of the wildtype BRCA1 allele was observed. Clinico-pathological variables in BRCA1-mutated ER+ cancer were more similar to BRCA2-mutated ER+ and sporadic ER+ breast cancer than to BRCA1 mutated ER- cancers. Conclusions As BRCA1-mutated ER+ tumors showed a BRCAness copy number profile and LOH, it is likely that the loss of a functional BRCA1 protein plays a role in tumorigenesis in BRCA1-mutated ER+ tumors. Therefore, we hypothesize that these tumors are sensitive to drugs targeting the BRCA1 gene defect. Citation Format: Lips EH, Debipersad R, Scheerman E, Mulder L, Sonke GS, van der Kolk LE, Wessling J, Hogervorst FBL, Nederlof PM. Estrogen receptor-positive breast cancer in BRCA1 mutation carriers shows a BRCAness profile, suggesting sensitivity to drugs targeting homologous recombination deficiency [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-12-03.
Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study
Authors: Franck E. Nicolini, Mael Heiblig, Stéphane Morisset, Denis Caillot, Valérie Coiteux, Aude Charbonnier, Françoise Huguet, Viviane Dubruille, Gabriel Etienne, Pascal Lenain, Francois Guilhot, Laurence Legros, Philippe Rousselot, Shanti Amé, Rémy DeFrance, Jeremy Ruby, Francois-Xavier Mahon, Delphine Rea
Journal: Blood (2015)
Correct Data and Meta-analytic Approaches Show the Reduced Risk of Concussion for Athletes Playing at Higher Altitudes
Authors: Gregory D. Myer, Daniel K. Schneider, Jane Khoury
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenström's Macroglobulinemia, on Patients' Survival
Authors: Evangelos Terpos, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Anna Tasidou, Dimitrios Christoulas, Maria Gavriatopoulou, Maria Gkotzamanidou, Maria Roussou, Theodora Papadaki, Meletios Athanasios Dimopoulos
Journal: Blood (2011)
MPs urge government to stop “bickering” with NHS leaders and solve funding crisis
Authors: Gareth Iacobucci
Journal: BMJ (2017)

An influential committee of MPs has urged the government to stop “bickering in public” with NHS leaders over the funding of the health service in England and provide an honest assessment of how current financial pressures were affecting the care of patients.

In a report published on Monday 27 February the House of Commons Committee of Public Accounts said that public disagreements between ministers and NHS England were damaging at a time when solutions were needed to tackle the severe and unsustainable financial strain facing the NHS.1

Tensions between the government and NHS leaders have risen in recent months after the repeated insistence from prime minister and health secretary that the NHS had received more money than it asked for from the government, a claim that NHS England’s chief …
Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy.
Authors: Neil P. Shah, John M. Nicoll, Susan Branford, Timothy P. Hughes, Ronald L. Paquette, Moshe Talpaz, Claude Nicaise, Fei Huang, Charles L. Sawyers
Journal: Blood (2005)
Importance of PGE2 signaling via the EP1 receptor in UVB skin carcinogenesis
Authors: Kathleen L. Tober, Jennifer M. Thomas, Jennifer L. Hatton, Kara J. Hill, Tatiana M. Oberyszyn
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

4297 

Chronic inflammation induced by repeated UVB exposure has been linked to development of skin tumors. The inflammatory mediator cyclooxygenase-2 (COX-2) and its enzymatic product prostaglandin E2 (PGE2) have been implicated in this carcinogenic response. While it is known that PGE2 exerts its effects via signaling through one of four E Prostanoid receptors, EP1 through EP4, the specific role of each receptor in skin tumor development is not clear. We have previously shown that topical application of celecoxib alone, ONO-8713, a specific EP1 receptor antagonist, alone, or a combination of these 2 drugs significantly inhibited several parameters associated with acute UVB-induced inflammation. Further immunohistochemical analysis demonstrated a significant decrease in UVB-induced p53 levels in the epidermis of mice treated topically with either celecoxib or ONO-8713 (p<0.02). This suggested that inhibition of PGE2 signaling might reduce UVB-mediated DNA damage and tumor development. Therefore, we compared the effects of chronic blockade of PGE2 production with blocking PGE2 signaling via the EP1 receptor on UVB-induced tumor development. SKH-1 hairless mice were treated topically with either 0.5 mg celecoxib, 0.05 mg ONO-8713 or a combination these drugs immediately following exposure to 2240 J/m2 UVB light three times weekly for 25 weeks. Topical treatment with celecoxib, ONO-8713, or the combination of these drugs decreased tumor grade as well as decreased tumor number (p<0.03) and size (p<0.05) compared to control treated mice. However, there was no significant difference in these parameters between treatment groups. This data suggests that inhibition of PGE2 signaling via the EP1 receptor is necessary but not sufficient to prevent UVB-induced skin tumor development. Supported by NIH NCI CA102340.
Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)
Authors: Alison R. Walker, Klaus H. Metzeler, Susan Geyer, Heiko Becker, Sebastian Schwind, Susan P. Whitman, John Curfman, Yue-Zhong Wu, Danilo Perrotti, Rebecca B. Klisovic, Ramiro Garzon, William Blum, Guido Marcucci
Journal: Blood (2011)
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively
Authors: Federica Costa, Marina Bolzoni, Rosanna Vescovini, Valentina Marchica, Fabrizio Accardi, Laura Notarfranchi, Benedetta Dalla Palma, Cristina Manferdini, Gina Lisignoli, Sabrina Manni, Francesco Piazza, Franco Aversa, Nicola Giuliani
Journal: Blood (2016)
Disruption of the NHR4 Domain Structure in AML1-ETO Abrogates Its Interaction with SON and Promotes AML1-ETO-Associated Leukemogenesis.
Authors: Eun-Young Ahn, Ming Yan, Oxana A Malakhova, Anita Boyapati, Hans Beier Ommen, Robert Hines, Peter Hokland, Dong-Er Zhang
Journal: Blood (2008)
Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy
Authors: Farhad Ravandi, Deborah A. Thomas, Susan O'Brien, Rebecca Garris, Stefan Faderl, Jianqin Shan, Gautam Borthakur, Jan A. Burger, Alessandra Ferrajoli, Partow Kebriaei, Richard Champlin, Zeev Estrov, Sa A. Wang, Jeffrey L. Jorgensen, Rajyalakshmi Luthra, Jorge E. Cortes, Hagop M. Kantarjian
Journal: Blood (2011)
Mechanism Research of Reversal in Multidrug Resistance by Magnetic Nanoparticle Fe3O4 Syndesis with 5-Bromotetrandrine and Daunomycin
Authors: Bao-An Chen, Wei-wei Wu, Jian Cheng, Feng Gao, Wen-lin Xu, Hui-lin Shen, Jia-hua Ding, Chong Gao, Yun-Yu Sun, Jun Wang, Gang Zhao, Huihui Song, Wen Bao, Xin-chen Sun, Hong-yan Cheng, Yu-xia Deng, Guo-hong Li, Li-jie Liu, Wen-ji Chen, Jue-qiong Wang, Peng Yuan, Xiao-ping Pei, Ning-na Chen, Xue-mei Wang
Journal: Blood (2008)
Labels on asthma inhalers about correct technique improve patient use, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

Attaching personalised labels explaining the correct use of dry powder inhalers achieves long term improvement in technique among patients with asthma, a small randomised study has shown.1

Dry powder inhalers are increasingly used for treating asthma because some patients find them easier to use than other types. But research has shown fewer than …
Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis
Authors: Mrinal M. Patnaik, Terra L Lasho, Christy Finke, Curtis A Hanson, Janice M Hodnefield, Ryan A Knudson, Rhett P Ketterling, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2012)
Efficacy and Safety of Cladribine in Adult Systemic Mastocytosis : A French Multicenter Study of 33 Patients.
Authors: Olivier Lortholary, Jacques Vargaftig, Frederic Feger, Fabienne Palmerini, Richard Delarue, Valerie Ferriole, Jean Marie Launay, Isabelle Bonte, Stephane Barete, Christine Bodemer, Sylvie Freytag, Philippe Casassus, Michel Arock, Patrice Dubreuil, Olivier Hermine
Journal: Blood (2004)
Trump calls on Congress to replace “unsustainable” Affordable Care Act
Authors: Michael McCarthy
Journal: BMJ (2017)

In his first speech before the US Congress, Tuesday 28 February, President Donald Trump called Democrats and Republicans to work with his administration to replace the Affordable Care Act, often called “Obamacare,” with reforms that “expand choice, increase access, lower costs, and, at the same time, provide better healthcare.”

Citing rising premiums and the limited choice of plans on the insurance marketplaces created by the 2010 health law, Trump said that Congress had to “save Americans from this imploding Obamacare disaster.”

Speaking for the Democrats in response, Steve Beshear, a former Democratic governor …
Abstract P5-16-22: Survival after adjuvant and neoadjuvant chemotherapy in elderly patients with triple negative breast cancer: A Cleveland Clinic experience
Authors: S Mohapatra, J Seepana, A Haddad, T Spiro, H Daw
Journal: Cancer Research (2017)

Abstract Background: Triple negative breast cancer (TNBC) comprises of approximately 15% of the total breast cancers. There is limited data on treatment outcome of these patients in elderly population. We report our experience with elderly patients with TNBC treated at our tertiary care centers. Objectives and rationale: 1. Percentage of TNBC patients who received neoadjuvant chemotherapy (NACT) vs. Adjuvant chemotherapy (ACT). 2. Chemotherapeutic agents used for NACT and ACT. 3. Progression free survival (PFS) and overall survival (OS) after neoadjuvant CT and adjuvant CT. 4. Outcomes between elderly patients 65-74 years vs. 75 years and above. Methods: With IRB approval, the Cleveland Clinic's database was used to identify TNBC patients treated between 2000 to 2013. OFS from the diagnosis of TNBC was the primary end point. Cox proportional hazard models with stepwise variable selections were used for data analysis. Results: A total of 223 patients, divided in to two groups, were prospectively followed. The age group from 65-74 years consisted of “Group A” (N=140, median 69) and 75 or older formed “Group B” (N= 83, median 80, maximum 92). Eighty eight percent had ductal carcinoma. Clinically majority had stage I (50%) and stage II (33%) disease; 17% had stage III disease and most tumors were poorly differentiated (74%, grade 3). Slightly more than half the patients had lumpectomies (55%); and in only 13% of cases (25/190) were margins positive. Patients who received neoadjuvant (NACT), aduvant chemotherapy (ACT) and radiation therapy (RT) were 65%, 53% and 38% respectively. For NACT primarily doxorubicin, cyclophosphamide and paclitaxel were used whereas for ACT it was docetaxel with cyclophosphamide. Group B had somewhat poorer performance status than younger patients (p=.05), received chemotherapy especially neoadjuvant therapy much less frequently (p&amp;lt;.0001). OS and PFS were significantly lower in Group B (p=0.001 and 0.007 respectively). This holds true even if one adjusts for performance status and use of chemotherapy (p=0.04 and 0.03 respectively). Conclusion: Among elderly patients with triple negative breast cancer, those above 75 years and older have poorer outcomes compared to those with age 65-74 years. However, this is a retrospective study and has limitations; prospective randomized studies are needed to confirm these findings. Citation Format: Mohapatra S, Seepana J, Haddad A, Spiro T, Daw H. Survival after adjuvant and neoadjuvant chemotherapy in elderly patients with triple negative breast cancer: A Cleveland Clinic experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-22.
The DASH Diet, 20 Years Later
Authors: Dori Steinberg, Gary G. Bennett, Laura Svetkey
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neoadjuvant chemotherapy for locally advanced cervical cancer: Experience at the Instituto Oncologico Nacional SOLCA Guayaquil.
Authors: Guillermo Paulson, Katherine Garcia, Mayra Santacruz, Ruth Ginger Engracia, Jose Francisco Mendoza
Journal: Journal of Clinical Oncology (2012)

e15571 Background: Cervical cancer is the most common malignancy of women in Ecuador. The main problem of concomitant chemo-radiotherapy (CRT) is the delay in starting radiation therapy, economic and logistical problems for high demand in radiotherapy. It has been neoadjuvant chemotherapy (NACT) followed by CRT the main treatment at our center in order to find an alternative to long waits before the start of radiotherapy. The aim of this study was to determine the response to NACT followed by CRT in terms progression-free survival (PFS) and overall survival (OS). Methods: diagnosed with invasive cervical cancer locally advanced stage II-III were analyzed retrospectively reviewed clinical records of pre-existing data from 2008 to 2010. Results: after meeting the criteria of exclusion, leaving 116 cases. The median age: 49 years (range: 28-82 years). The histology was 73% (85) squamous cell carcinoma, 26% (30) adenocarcinoma and 0.9% (1) not specified. Patients with stage IIB: 81.9% (95), IIIA: 10.3% (12), IIIB: 7.8% (9). Of the 116 patients 69% (80) received NACT. The main NACT was paclitaxel 175mg/m2 + Cisplatin 75mg/m2 every 3 weeks 63.8% (74), the remaining group received another protocol, the median number of cycles of NACT was 5 (1 - 8 cycles), the start of radiotherapy since the conclusion of NACT was 53 days on average (1 to 285 days) and the main regimen of CRT concomitant was cisplatin 40mg/m2 weekly 47.5% (38). In the 49 patients who underwent NACT followed by CRT, a radiological study showed, complete response (CR) 38.8% (19), 18.4% partial response (PR) (9), disease progression (DP) 12.2% (6), stable disease (SD) 8.2% (4) and the end of treatment evaluation gynecological was performed and CR was obtained in 59.2% (29). Persistent or progressive disease after treatment was 22.4% (11), recurrence was 12.2% (6), local recurrence 2.0% (1), distant metastasis 10.2% (5). OS of NACT followed by CRT was 93.9% (46) and PFS was 65.3% (32), OS after CR was 96% (25 / 1) and then 91.7% PR (24 / 2) with p: 0.439. Conclusions: NACT followed by CRT is a valid option because it improves disease-related symptoms, but OS did not improve significantly even after CR.